Genesis HealthCare System issued the following announcement on Oct. 28.
The Genesis Heart and Vascular team utilize two advanced technologies to treat structural heart disease: Transcatheter aortic valve replacement (TAVR) and MitraClip. TAVR is a minimally invasive way of treating heart valve disease, which is the most common form of structural heart disease. Patients only stay in the hospital for an average of one or two days. After that, they can resume normal activities within a week.
MitraClip is the newest addition to the Structural Heart Program at Genesis. It is minimally invasive and used to treat mitral regurgitation, also known as a leaky heart valve. MitraClip helps the mitral valve to close correctly and restore normal blood flow to the heart. Patients stay in the hospital for one to three days after the procedure.
Original source can be found here.
Source: Genesis HealthCare System
Alerts Sign-up